Wei Peng Email & Phone Number

Shanghai, China

• Selected portfolios: Santa Ana Bio, Rgenta, Tune, MediLink, AllianThera, ABM Tx, Base Tx, Bristar, Unicet, Migrasome, Velavigo.
• Lead a cross-functional team to identify new trends in therapeutics through systematic analyses of unmet medical needs and new technology platforms (BsAb, ADC, TRT, cell and gene therapy, degrader, mRNA, siRNA.
• Search and evaluate early stage investment deals in a variety of therapeutics, including immunology, oncology, CNS and metabolic diseases.
• Incubate innovative translational projects from academia and recruit team members.
• Manage 30+ portfolio companies around the world and provide value add services, serving as directors and observers on the board, facilitating out-licensing deals.
• Establish external collaborations with international VC/PE funds, big pharma, biotech incubators and academia.

• Built strong cross-functional teams from R&D and clinical development, delivering comprehensive strategies for successful expansion into new therapeutic areas, such as autoimmune diseases and hematological cancers.
• Led in-depth reviews of novel targets, MoAs and modalities, proposing 10+ internal pipelines, external innovation projects and organizational support, managing early research programs.
• Conducted due diligence and analyzed competitive landscape for 10+ in-license opportunities, collaborating closely with business development and clinical functions.

Beijing, China

• Invented new enzymatic solutions, including 10 global patents/product launches, to increase efficiency for biopharma, animal health, food and wastewater industries.
• Led cross-functional teams to identify new areas for business growth in China, evaluating both technological feasibility and marketing potential.
• Supported the Head of Global Innovation and Head of Regional Business Development on strategy formulation and technical/business reviews with senior leadership.
• Collaborated with internal functions, academia and regulatory institutions for biotech innovations, such as high throughput screening technology and synthetic biology.
• Managed multiple research projects/initiatives and supervised team members.

Greater Boston Area

• Led a group of scientists and demonstrated the impact of amino acid restriction on inflammation and aging through GCN2 kinase pathway, reported by the Washington Post.
• Established the protective function of the small molecule halofuginone in ischemia injury.
• Developed in vivo protocols of inflammation induced by bacterial pathogens.

Greater Boston Area

• Investigated the mechanism of cortisol-induced obesity, using an adipocyte-specific glucocorticoid receptor knockout mouse, and revealed a connection with PGC-1alpha.
• Wrote three grants and developed a protocol for inducing obesity by oral delivery.
• Collaborated with colleagues to discover the role of Rho kinases in metabolic diseases.

Doctor Of Philosophy (Phd), Immunology

• Created a screening system for antigen-presenting molecules in cancer and infectious diseases. • Cloned genes in CD1 pathway, by which.

Iaeste Scholar

Bachelor Of Science (B.Sc.), Biochemistry

Special Class For The Gifted Young/Biology